Armata Pharmaceuticals, Inc. financial data

Symbol
ARMP on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
5005 Mcconnell Ave, Los Angeles, CA
State of incorporation
WA
Fiscal year end
December 31
Former names
AmpliPhi Biosciences Corp (to 5/8/2019), TARGETED GENETICS CORP /WA/ (to 2/11/2011)
Latest financial report
10-K - Q4 2024 - Mar 21, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 26.6 % -69%
Debt-to-equity -305 % +97.9%
Return On Equity 37.5 % -99.6%
Return On Assets -18.3 % +72.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares +0.1%
Common Stock, Shares, Outstanding 36.2M shares +0.17%
Entity Public Float 30.3M USD +142%
Common Stock, Value, Issued 362K USD +0.28%
Weighted Average Number of Shares Outstanding, Basic 36.2M shares +0.24%
Weighted Average Number of Shares Outstanding, Diluted 59.1M shares +63.7%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13.2M USD +13.2%
Operating Income (Loss) -42.4M USD -3.78%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -18.9M USD +72.6%
Earnings Per Share, Basic -0.52 USD/shares +72.8%
Earnings Per Share, Diluted -0.89 USD/shares +53.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.29M USD -31.3%
Other Assets, Current 744K USD -77.9%
Assets, Current 11.3M USD -41%
Property, Plant and Equipment, Net 13.2M USD +5.43%
Operating Lease, Right-of-Use Asset 41.7M USD -6.78%
Intangible Assets, Net (Excluding Goodwill) 10.3M USD 0%
Goodwill 3.49M USD 0%
Other Assets, Noncurrent 975K USD -60.5%
Assets 86.4M USD -12.1%
Accounts Payable, Current 766K USD -51.7%
Liabilities, Current 48.2M USD +193%
Deferred Income Tax Liabilities, Net 3.08M USD 0%
Operating Lease, Liability, Noncurrent 27.7M USD -3.11%
Liabilities 134M USD +3.09%
Retained Earnings (Accumulated Deficit) -328M USD -6.13%
Stockholders' Equity Attributable to Parent -48M USD -49.8%
Liabilities and Equity 86.4M USD -12.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.6M USD +39.8%
Net Cash Provided by (Used in) Financing Activities 34.9M USD +18%
Net Cash Provided by (Used in) Investing Activities -250K USD +87.6%
Common Stock, Shares Authorized 217M shares 0%
Common Stock, Shares, Issued 36.2M shares +0.17%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 24.1M USD +141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.8M USD -23.2%
Deferred Tax Assets, Valuation Allowance 84.2M USD +12%
Deferred Tax Assets, Gross 97.1M USD +11.9%
Operating Lease, Liability 32.1M USD -15.6%
Depreciation 1.3M USD +30%
Payments to Acquire Property, Plant, and Equipment 250K USD -87.6%
Lessee, Operating Lease, Liability, to be Paid 64.9M USD -13.7%
Property, Plant and Equipment, Gross 26.4M USD +8.23%
Operating Lease, Liability, Current 4.43M USD -53.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.29M USD -0.26%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.72M USD -52.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 32.7M USD +3.16%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.45M USD -4.75%
Deferred Tax Assets, Operating Loss Carryforwards 53.6M USD +15.1%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.62M USD +3.01%
Operating Lease, Payments 3.36M USD -35.4%
Additional Paid in Capital 279M USD +1.07%
Depreciation, Depletion and Amortization 317K USD +37.8%
Share-based Payment Arrangement, Expense 2.89M USD +208%
Interest Expense 2.72M USD